Safety of Dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes

Current Drug Safety

Volumn 6, Issue 5, 2011, Pages 304-309

  Mikhail, Nasser ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; DPP 4 inhibitors; Incretins; Safety

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; IRBESARTAN; LINAGLIPTIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; RIFAMPICIN; RITONAVIR; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BODY WEIGHT; BULLOUS PEMPHIGOID; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GENITAL TRACT INFECTION; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; LEUKOPENIA; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PANCREATITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THYROID CANCER; VASCULITIS; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; TIME FACTORS;

EID: 84855849888     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798918700     Document Type: Article

References (53)

1. Mikhail N. Incretin mimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008; 17: 845-53.
2. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220-24.
3. Mikhail N, Cope D. Appraisal of saxagliptin as treatment of type 2 diabetes. Curr Drug Ther 2010; 5: 111-17.
4. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010; 90: 131-40.
5. Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. New York, Raven Press 1984.
6. Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010; 88: 125-31.
7. Ahmad S, Wang L, Ward PE. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharm Exp Ther 1992; 260: 1257-61.
8. Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors. An increased risk of angioedema. Hypertension 2009; 54: 468-70. Editorial.
9. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Diabetes Care 2007; 30: 1335-43.
10. Hermansen K, Kipnes M, Luo E, et al. for the Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes inadequately controlled on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-45.
11. Chacra AR, Tan GH, Apanovitch A, et al. for the CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract 2009; 63: 1395-406.
12. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylurea. Diabetes Obes Metab 2008; 10: 1047-56.
13. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-61.
14. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
15. De Heer J, Holst J. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438-43.
16. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obesity Metab 2010; 12: 167-77.
17. Fonesca V, Dejager S, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-55.
18. Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabetes Obes Metab 2009; 11: 1145-52.
19. Hollander P, Li J, Allen E, Chen R, for the CV181-013. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94: 4810-19.
20. Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 2011; 65: 154-64.
21. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 653-61.
22. Garber AJ, Schweizer A, Baron A, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166-74.
23. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.
24. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011; 7: 49-57.
25. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008 (2): CD006739.
26. Willemen MJ, Mantel-Teeuisse AK, Strauss SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the report of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011; 34: 369-74.
27. Grouzmann E, Monod M, Landis B, et al. Loss of dipeptidyl peptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB 2002; 16: 1132-34.
28. Onglyza (saxagliptin). Prescribing information. Bristol-Myers Squibb. Princeton, NJ 08543, USA. July 2009.
29. Tradjenta (linagliptin). Prescribing Information. 2011. Boehringer Ingelheim Pharmaceuticals, Inc. Rdgefield, CT 06877 USA.
30. Pratley RE, Kipnes MS, Fleck PR, et al. on behalf of the Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167-76.
31. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitorassociated angioedema. Hypertension 2009; 54: 516-23.
32. Desai S, Brinker A, Swann J, Iyasu S. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med 2010; 170: 1169-71.
33. Skalli S, Wion-Barbot N, Baudrant M, et al. Angio-edema induced by dual dipeptidyl peptidase inhibtor and angiotensin II receptor blocker: a first case report. Diabet Med 2010: 27: 485-88.
34. Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV activity in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008; 51: 141-47.
35. Byrd JB, Shreevatsa A, Putlur P, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol 2007; 120: 403-8.
36. Januvia (sitagliptin). Prescribing Information. Merck& CO., INC., Whitehouse Station, NJ 08889, USA 2011.
37. Skandalis K, Spirova M, Gaitanis G, et al. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2011; April [Epub ahead of print]. Accessed October 31, 2011.
38. Pasmatzi E, Monastirli A, Habeos J, et al. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of 2 cases. Diabetes Care 2011; 34: e133.
39. Raynaud F, Bauvois B, Gerbaud P, Evain-Brion D. Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology. J Cell Physiol 1992; 151: 378-85.
40. Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011; 223: 133-35.
41. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardiocerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12: 485-94.
42. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64: 984-90.
43. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-27.
44. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-354.
45. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1 based therapies. Gastroenterology 2011; 141: 150-56.
46. Pitocco D, Zaccardi F, Martini F, et al. Severe leucopenia associated with sitagliptin use. Diabetes Res Clin Pract 2011; 91: e30-e32.
47. Novartis Pharmaceuticals UK Ltd. Galvus UK. Summary of product characteristics. Camberley. Srrey, UK. January 2011. http://www.medicines.org.uk/emc/medicine/20734/SPC/. Accessed August 8, 2011.
48. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12: 648-58.
49. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13; 939-946.
50. Januvia prescribing information. European Medicines Agency. http:www:ema.europea,eu/docs/en_GB/document. Accessed October 28, 2011.
51. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a randomized placebocontrolled trial. Diabetes Obes Metab 2011; 13: 947-54.
52. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obesity Metab 2011; 13: 258-67.
53. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab2011; 13: 65-74.